{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T21:10:10Z","timestamp":1794604210295,"version":"4.9.1"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,19]],"date-time":"2021-11-19T00:00:00Z","timestamp":1637280000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013248","name":"Family Process Institute","doi-asserted-by":"publisher","award":["JR18\/00051"],"award-info":[{"award-number":["JR18\/00051"]}],"id":[{"id":"10.13039\/100013248","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010198","name":"Gobierno de Espa\u00f1a Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","award":["PID2020-120336RB-I00"],"award-info":[{"award-number":["PID2020-120336RB-I00"]}],"id":[{"id":"10.13039\/501100010198","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014440","name":"Spain Ministry of Science and Innovation","doi-asserted-by":"publisher","award":["SAF2017-89714-R"],"award-info":[{"award-number":["SAF2017-89714-R"]}],"id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011596","name":"Education Culture and Sports Department","doi-asserted-by":"publisher","award":["AICO\/2019\/250"],"award-info":[{"award-number":["AICO\/2019\/250"]}],"id":[{"id":"10.13039\/501100011596","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011596","name":"Education Culture and Sports Department","doi-asserted-by":"publisher","award":["Gent T CDEI-04\/20-A"],"award-info":[{"award-number":["Gent T CDEI-04\/20-A"]}],"id":[{"id":"10.13039\/501100011596","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011596","name":"Education Culture and Sports Department","doi-asserted-by":"publisher","award":["PROMETEO\/2019\/032"],"award-info":[{"award-number":["PROMETEO\/2019\/032"]}],"id":[{"id":"10.13039\/501100011596","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI18\/00209"],"award-info":[{"award-number":["PI18\/00209"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003359","name":"Generalitat Valenciana","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003359","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.biopha.2021.112460","type":"journal-article","created":{"date-parts":[[2021,12,2]],"date-time":"2021-12-02T07:44:47Z","timestamp":1638431087000},"page":"112460","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"special_numbering":"C","title":["Beneficial effects of PCSK9 inhibition with alirocumab in familial hypercholesterolemia involve modulation of new immune players"],"prefix":"10.1016","volume":"145","author":[{"given":"Patrice","family":"Marques","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Domingo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arantxa","family":"Rubio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Martinez-Herv\u00e1s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan F.","family":"Ascaso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Piqueras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 T.","family":"Real","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-Jesus","family":"Sanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.biopha.2021.112460_bib1","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.pcad.2016.07.006","article-title":"Familial hypercholesterolemia: advances in recognition and therapy","volume":"59","author":"Cartier","year":"2016","journal-title":"Prog. Cardiovasc Dis."},{"issue":"2","key":"10.1016\/j.biopha.2021.112460_bib2","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1007\/s11883-014-0482-5","article-title":"Familial hypercholesterolemia--epidemiology, diagnosis, and screening","volume":"17","author":"Singh","year":"2015","journal-title":"Curr. Atheroscler. Rep."},{"key":"10.1016\/j.biopha.2021.112460_bib3","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/6508709","article-title":"Simvastatin effects on inflammation and platelet activation markers in hypercholesterolemia","volume":"2018","author":"Barale","year":"2018","journal-title":"Biomed. Res. Int."},{"issue":"7","key":"10.1016\/j.biopha.2021.112460_bib4","doi-asserted-by":"crossref","first-page":"11324","DOI":"10.3390\/ijms150711324","article-title":"Endothelial dysfunction in chronic inflammatory diseases","volume":"15","author":"Steyers","year":"2014","journal-title":"Int J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.biopha.2021.112460_bib5","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3390\/jcm8010018","article-title":"Novel immune features of the systemic inflammation associated with primary hypercholesterolemia: changes in cytokine\/chemokine profile, increased platelet and leukocyte activation","volume":"8","author":"Collado","year":"2018","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.biopha.2021.112460_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.104916","article-title":"Clinical approach to the inflammatory etiology of cardiovascular diseases","volume":"159","author":"Ruscica","year":"2020","journal-title":"Pharm. Res."},{"key":"10.1016\/j.biopha.2021.112460_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.biocel.2021.106066","article-title":"Primary hypercholesterolemia and development of cardiovascular disorders: Cellular and molecular mechanisms involved in low-grade systemic inflammation and endothelial dysfunction","volume":"139","author":"Collado","year":"2021","journal-title":"Int. J. Biochem. Cell Biol."},{"issue":"10","key":"10.1016\/j.biopha.2021.112460_bib8","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/S2213-8587(16)30041-9","article-title":"Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel","volume":"4","author":"Santos","year":"2016","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.biopha.2021.112460_bib9","doi-asserted-by":"crossref","first-page":"707","DOI":"10.3389\/fphar.2018.00707","article-title":"Familial hypercholesterolemia: new horizons for diagnosis and effective management","volume":"9","author":"Mytilinaiou","year":"2018","journal-title":"Front. Pharm."},{"issue":"12","key":"10.1016\/j.biopha.2021.112460_bib10","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1194\/jlr.R026658","article-title":"The PCSK9 decade","volume":"53","author":"Lambert","year":"2012","journal-title":"J. Lipid Res."},{"issue":"3","key":"10.1016\/j.biopha.2021.112460_bib11","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/biof.1619","article-title":"Beyond cholesterol metabolism: the pleiotropic effects of proprotein convertase subtilisin\/kexin type 9 (PCSK9). Genetics, mutations, expression, and perspective for long-term inhibition","volume":"46","author":"Cesaro","year":"2020","journal-title":"Biofactors"},{"issue":"4","key":"10.1016\/j.biopha.2021.112460_bib12","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s11883-015-0491-z","article-title":"Genetics of familial hypercholesterolemia","volume":"17","author":"Brautbar","year":"2015","journal-title":"Curr. Atheroscler. Rep."},{"issue":"1","key":"10.1016\/j.biopha.2021.112460_bib13","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/s41598-017-00316-3","article-title":"Therapeutic efficacy and safety of PCSK9-monoclonal antibodies on familial hypercholesterolemia and statin-intolerant patients: a meta-analysis of 15 randomized controlled trials","volume":"7","author":"Qian","year":"2017","journal-title":"Sci. Rep."},{"issue":"11","key":"10.1016\/j.biopha.2021.112460_bib14","doi-asserted-by":"crossref","first-page":"e136","DOI":"10.1093\/cvr\/cvaa212","article-title":"Inclisiran for the treatment of hypercholesterolaemia: implications and unanswered questions from the ORION trials","volume":"116","author":"Cupido","year":"2020","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.biopha.2021.112460_bib15","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/joim.12758","article-title":"PCSK9 plays a novel immunological role in oxidized LDL-induced dendritic cell maturation and activation of T cells from human blood and atherosclerotic plaque","volume":"284","author":"Liu","year":"2018","journal-title":"J. Intern. Med."},{"issue":"5","key":"10.1016\/j.biopha.2021.112460_bib16","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1177\/2047487319839179","article-title":"Impact of PCSK9 inhibitors on the quality of life of patients at high cardiovascular risk","volume":"27","author":"Cesaro","year":"2020","journal-title":"Eur. J. Prev. Cardiol."},{"issue":"4","key":"10.1016\/j.biopha.2021.112460_bib17","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.jacc.2006.09.034","article-title":"CXCL16 is a marker of inflammation, atherosclerosis, and acute coronary syndromes in humans","volume":"49","author":"Lehrke","year":"2007","journal-title":"J. Am. Coll. Cardiol."},{"issue":"3","key":"10.1016\/j.biopha.2021.112460_bib18","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1172\/JCI15555","article-title":"Decreased atherosclerosis in CX3CR1-\/- mice reveals a role for fractalkine in atherogenesis","volume":"111","author":"Lesnik","year":"2003","journal-title":"J. Clin. Investig."},{"issue":"6","key":"10.1016\/j.biopha.2021.112460_bib19","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1089\/jir.2008.0027","article-title":"Monocyte chemoattractant protein-1 (MCP-1): an overview","volume":"29","author":"Deshmane","year":"2009","journal-title":"J. Interferon. Cytokine Res."},{"issue":"5","key":"10.1016\/j.biopha.2021.112460_bib20","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.clnu.2013.01.008","article-title":"Associations of CXCL16\/CXCR6 with carotid atherosclerosis in patients with metabolic syndrome","volume":"32","author":"Lv","year":"2013","journal-title":"Clin. Nutr."},{"issue":"2","key":"10.1016\/j.biopha.2021.112460_bib21","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1093\/cvr\/cvu115","article-title":"Insulin resistance aggravates atherosclerosis by reducing vascular smooth muscle cell survival and increasing CX3CL1\/CX3CR1 axis","volume":"103","author":"Mart\u00ednez-Herv\u00e1s","year":"2014","journal-title":"Cardiovasc. Res."},{"issue":"9","key":"10.1016\/j.biopha.2021.112460_bib22","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1507\/endocrj.EJ15-0731","article-title":"CCL2 level is elevated with metabolic syndrome and CXCL10 level is correlated with visceral fat area in obese children","volume":"63","author":"Ishii","year":"2016","journal-title":"Endocr. J."},{"issue":"2","key":"10.1016\/j.biopha.2021.112460_bib23","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3758\/BF03193146","article-title":"G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences","volume":"39","author":"Faul","year":"2007","journal-title":"Behav. Res. Methods"},{"issue":"9","key":"10.1016\/j.biopha.2021.112460_bib24","doi-asserted-by":"crossref","first-page":"895","DOI":"10.5551\/jat.RV17012","article-title":"Lipid lowering therapy and circulating PCSK9 concentration","volume":"24","author":"Nozue","year":"2017","journal-title":"J. Atheroscler. Thromb."},{"key":"10.1016\/j.biopha.2021.112460_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2021.06.017","article-title":"Evolocumab and alirocumab increases total PCSK9 plasma levels in hypocholesterolemic patients: Investigation of the basic molecular mechanisms","volume":"331","author":"Ferri","year":"2021","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1016\/j.biopha.2021.112460_bib26","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.atherosclerosis.2010.10.002","article-title":"Children with familial hypercholesterolemia are characterized by an inflammatory imbalance between the tumor necrosis factor alpha system and interleukin-10","volume":"214","author":"Narverud","year":"2011","journal-title":"Atherosclerosis"},{"issue":"4","key":"10.1016\/j.biopha.2021.112460_bib27","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1093\/jn\/136.4.877","article-title":"Triglyceride-rich HDL3 from patients with familial hypercholesterolemia are less able to inhibit cytokine release or to promote cholesterol efflux","volume":"136","author":"Ottestad","year":"2006","journal-title":"J. Nutr."},{"issue":"4","key":"10.1016\/j.biopha.2021.112460_bib28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0121516","article-title":"Elevated atherosclerosis-related gene expression, monocyte activation and microparticle-release are related to increased lipoprotein-associated oxidative stress in familial hypercholesterolemia","volume":"10","author":"Hjuler Nielsen","year":"2015","journal-title":"PLoS One"},{"issue":"20","key":"10.1016\/j.biopha.2021.112460_bib29","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1093\/eurheartj\/ehx002","article-title":"PCSK9 monoclonal antibodies reverse the pro-inflammatory profile of monocytes in familial hypercholesterolaemia","volume":"38","author":"Bernelot Moens","year":"2017","journal-title":"Eur. Heart J."},{"issue":"1\u20132","key":"10.1016\/j.biopha.2021.112460_bib30","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s11010-011-1028-6","article-title":"PCSK9 siRNA inhibits HUVEC apoptosis induced by ox-LDL via Bcl\/Bax-caspase9-caspase3 pathway","volume":"359","author":"Wu","year":"2012","journal-title":"Mol. Cell Biochem."},{"issue":"9","key":"10.1016\/j.biopha.2021.112460_bib31","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1089\/ars.2014.6054","article-title":"Hemodynamic shear stress via ROS modulates PCSK9 expression in human vascular endothelial and smooth muscle cells and along the mouse aorta","volume":"22","author":"Ding","year":"2015","journal-title":"Antioxid. Redox Signal"},{"issue":"3","key":"10.1016\/j.biopha.2021.112460_bib32","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.freeradbiomed.2011.11.002","article-title":"Role of reactive oxygen and nitrogen species in the vascular responses to inflammation","volume":"52","author":"Kvietys","year":"2012","journal-title":"Free Radic. Biol. Med."},{"issue":"1","key":"10.1016\/j.biopha.2021.112460_bib33","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1161\/ATVBAHA.112.254870","article-title":"Arterial and venous endothelia display differential functional fractalkine (CX3CL1) expression by angiotensin-II","volume":"33","author":"Rius","year":"2013","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"10","key":"10.1016\/j.biopha.2021.112460_bib34","doi-asserted-by":"crossref","first-page":"H1919","DOI":"10.1152\/ajpheart.00910.2011","article-title":"Expression and functional significance of NADPH oxidase 5 (Nox5) and its splice variants in human blood vessels","volume":"302","author":"Pandey","year":"2012","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"issue":"3","key":"10.1016\/j.biopha.2021.112460_bib35","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.smim.2014.02.009","article-title":"TNF and MAP kinase signalling pathways","volume":"26","author":"Sabio","year":"2014","journal-title":"Semin Immunol."},{"issue":"4","key":"10.1016\/j.biopha.2021.112460_bib36","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1093\/cvr\/cvv178","article-title":"Cross-talk between LOX-1 and PCSK9 in vascular tissues","volume":"107","author":"Ding","year":"2015","journal-title":"Cardiovasc. Res."},{"issue":"4","key":"10.1016\/j.biopha.2021.112460_bib37","doi-asserted-by":"crossref","first-page":"931","DOI":"10.3892\/ijmm.2012.1072","article-title":"PCSK9 siRNA suppresses the inflammatory response induced by oxLDL through inhibition of NF-kappaB activation in THP-1-derived macrophages","volume":"30","author":"Tang","year":"2012","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.biopha.2021.112460_bib38","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.atherosclerosis.2017.04.023","article-title":"New role of PCSK9 in atherosclerotic inflammation promotion involving the TLR4\/NF-kappaB pathway","volume":"262","author":"Tang","year":"2017","journal-title":"Atherosclerosis"},{"issue":"2","key":"10.1016\/j.biopha.2021.112460_bib39","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.immuni.2019.06.005","article-title":"The cytokine TNF promotes transcription factor SREBP activity and binding to inflammatory genes to activate macrophages and limit tissue repair","volume":"51","author":"Kusnadi","year":"2019","journal-title":"Immunity"},{"issue":"7","key":"10.1016\/j.biopha.2021.112460_bib40","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a004754","article-title":"Regulation of cholesterol and fatty acid synthesis","volume":"3","author":"Ye","year":"2011","journal-title":"Cold Spring Harb. Perspect. Biol."},{"issue":"2","key":"10.1016\/j.biopha.2021.112460_bib41","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1194\/jlr.M700443-JLR200","article-title":"Sterol-dependent regulation of proprotein convertase subtilisin\/kexin type 9 expression by sterol-regulatory element binding protein-2","volume":"49","author":"Jeong","year":"2008","journal-title":"J. Lipid Res."},{"issue":"4","key":"10.1016\/j.biopha.2021.112460_bib42","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s13167-017-0106-6","article-title":"PCSK9 signaling pathways and their potential importance in clinical practice","volume":"8","author":"Wicinski","year":"2017","journal-title":"Epma J."},{"key":"10.1016\/j.biopha.2021.112460_bib43","doi-asserted-by":"crossref","first-page":"294","DOI":"10.3389\/fphys.2014.00294","article-title":"Platelets and their chemokines in atherosclerosis-clinical applications","volume":"5","author":"von Hundelshausen","year":"2014","journal-title":"Front Physiol."},{"issue":"1","key":"10.1016\/j.biopha.2021.112460_bib44","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1161\/CIRCULATIONAHA.120.046290","article-title":"PCSK9 (Proprotein Convertase Subtilisin\/Kexin 9) enhances platelet activation, thrombosis, and myocardial infarct expansion by binding to platelet CD36","volume":"143","author":"Qi","year":"2021","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.biopha.2021.112460_bib45","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.numecd.2019.09.012","article-title":"Platelet function and activation markers in primary hypercholesterolemia treated with anti-PCSK9 monoclonal antibody: a 12-month follow-up","volume":"30","author":"Barale","year":"2020","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"issue":"8","key":"10.1016\/j.biopha.2021.112460_bib46","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.jacc.2017.11.069","article-title":"PCSK9 as a positive modulator of platelet activation","volume":"71","author":"Camera","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"issue":"2","key":"10.1016\/j.biopha.2021.112460_bib47","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.atherosclerosis.2007.08.014","article-title":"Primed polymorphonuclear leukocytes constitute a possible link between inflammation and oxidative stress in hyperlipidemic patients","volume":"197","author":"Mazor","year":"2008","journal-title":"Atherosclerosis"},{"issue":"4","key":"10.1016\/j.biopha.2021.112460_bib48","first-page":"626","article-title":"Role and analysis of monocyte subsets in cardiovascular disease. Joint consensus document of the European Society of Cardiology (ESC) Working Groups \"Atherosclerosis & Vascular Biology\" and \"Thrombosis\"","volume":"116","author":"Weber","year":"2016","journal-title":"Thromb. Haemost."},{"issue":"2","key":"10.1016\/j.biopha.2021.112460_bib49","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.atherosclerosis.2014.10.106","article-title":"Pro-inflammatory monocyte-macrophage polarization imbalance in human hypercholesterolemia and atherosclerosis","volume":"237","author":"Fadini","year":"2014","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.biopha.2021.112460_bib50","doi-asserted-by":"crossref","first-page":"680","DOI":"10.3389\/fimmu.2019.00680","article-title":"The pivotal role of regulatory T cells in the regulation of innate immune cells","volume":"10","author":"Okeke","year":"2019","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.biopha.2021.112460_bib51","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1177\/2047487318815320","article-title":"Long-term exposure to air pollution raises circulating levels of proprotein convertase subtilisin\/kexin type 9 in obese individuals","volume":"26","author":"Macchi","year":"2019","journal-title":"Eur. J. Prev. Cardiol."},{"issue":"1","key":"10.1016\/j.biopha.2021.112460_bib52","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1186\/s12916-019-1457-8","article-title":"Therapeutic effect of nanoliposomal PCSK9 vaccine in a mouse model of atherosclerosis","volume":"17","author":"Momtazi-Borojeni","year":"2019","journal-title":"BMC Med."},{"issue":"10","key":"10.1016\/j.biopha.2021.112460_bib53","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1038\/aps.2013.92","article-title":"Chemokines and atherosclerosis: focus on the CX3CL1\/CX3CR1 pathway","volume":"34","author":"Apostolakis","year":"2013","journal-title":"Acta Pharm. Sin."},{"issue":"20","key":"10.1016\/j.biopha.2021.112460_bib54","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1093\/eurheartj\/ehx098","article-title":"Cholesterol, CCR2, and monocyte phenotypes in atherosclerosis","volume":"38","author":"Nahrendorf","year":"2017","journal-title":"Eur. Heart J."},{"issue":"7","key":"10.1016\/j.biopha.2021.112460_bib55","doi-asserted-by":"crossref","first-page":"3508","DOI":"10.1074\/jbc.M115.664706","article-title":"Suppressor of cytokine Signaling-3 (SOCS-3) induces proprotein convertase subtilisin kexin Type 9 (PCSK9) expression in hepatic HepG2 cell line","volume":"291","author":"Ruscica","year":"2016","journal-title":"J. Biol. Chem."},{"issue":"10","key":"10.1016\/j.biopha.2021.112460_bib56","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1194\/jlr.M051326","article-title":"Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin","volume":"55","author":"K\u00fchnast","year":"2014","journal-title":"J. Lipid Res."},{"issue":"2","key":"10.1016\/j.biopha.2021.112460_bib57","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1194\/jlr.M078360","article-title":"PCSK9 deficiency reduces atherosclerosis, apolipoprotein B secretion, and endothelial dysfunction","volume":"59","author":"Sun","year":"2018","journal-title":"J. Lipid Res."},{"issue":"32","key":"10.1016\/j.biopha.2021.112460_bib58","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1093\/eurheartj\/ehx260","article-title":"The AT04A vaccine against proprotein convertase subtilisin\/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden.CETP mice","volume":"38","author":"Landlinger","year":"2017","journal-title":"Eur. Heart J."},{"issue":"2","key":"10.1016\/j.biopha.2021.112460_bib59","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.3892\/mmr.2017.6803","article-title":"Investigation of highly expressed PCSK9 in atherosclerotic plaques and ox-LDL-induced endothelial cell apoptosis","volume":"16","author":"Li","year":"2017","journal-title":"Mol. Med. Rep."},{"issue":"23","key":"10.1016\/j.biopha.2021.112460_bib60","doi-asserted-by":"crossref","first-page":"9037","DOI":"10.1074\/jbc.RA119.008094","article-title":"Diet-induced hepatic steatosis abrogates cell-surface LDLR by inducing de novo PCSK9 expression in mice","volume":"294","author":"Lebeau","year":"2019","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.biopha.2021.112460_bib61","doi-asserted-by":"crossref","first-page":"H874","DOI":"10.1152\/ajpheart.00096.2012","article-title":"Cross-talk between TLR4-MyD88-NF-\u03baB and SCAP-SREBP2 pathways mediates macrophage foam cell formation","volume":"304","author":"Li","year":"2013","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"issue":"18","key":"10.1016\/j.biopha.2021.112460_bib62","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"New Engl. J. Med."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332221012464?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332221012464?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T06:32:25Z","timestamp":1781764345000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332221012464"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":62,"alternative-id":["S0753332221012464"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2021.112460","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Beneficial effects of PCSK9 inhibition with alirocumab in familial hypercholesterolemia involve modulation of new immune players","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2021.112460","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"112460"}}